Ligand Pharmaceuticals Inc. - Equities research analysts at Craig Hallum upped their Q1 2016 earnings estimates for shares of Ligand Pharmaceuticals in a research report issued to clients and investors on Thursday, according to Zacks Investment Research . Craig Hallum analyst M. Tiampo now anticipates that the brokerage will post earnings of $0.46 per share for the quarter, up from their prior forecast of $0.44.